MA37525B1 - Agents pour le traitement de troubles mettant en jeu la modulation de récepteurs de ryanodine - Google Patents

Agents pour le traitement de troubles mettant en jeu la modulation de récepteurs de ryanodine

Info

Publication number
MA37525B1
MA37525B1 MA37525A MA37525A MA37525B1 MA 37525 B1 MA37525 B1 MA 37525B1 MA 37525 A MA37525 A MA 37525A MA 37525 A MA37525 A MA 37525A MA 37525 B1 MA37525 B1 MA 37525B1
Authority
MA
Morocco
Prior art keywords
agents
treatment
disorders involving
ryanodine receptors
involving modulation
Prior art date
Application number
MA37525A
Other languages
English (en)
Other versions
MA37525A1 (fr
Inventor
Jiaming Yan
Sandro Belvedere
Yael Webb
Marc Bertrand
Nicole Villeneuve
Original Assignee
Servier Lab
Armgo Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Armgo Pharma Inc filed Critical Servier Lab
Publication of MA37525A1 publication Critical patent/MA37525A1/fr
Publication of MA37525B1 publication Critical patent/MA37525B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/36—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/841—Muscles; heart

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)

Abstract

La présente invention concerne des dérivés 1,4-benzothiazépines et leur utilisation pour traiter des états, des troubles et des maladies associés à des récepteurs de ryanodine (ryrs) qui régulent la fonction des canaux calciques dans les cellules. L'invention concerne également des compositions pharmaceutiques comprenant les composés et leurs utilisations pour traiter des maladies et des états associés à ryrs, en particulier des troubles cardiaques, musculo-squelettiques et du système nerveux central (snc).
MA37525A 2012-05-11 2014-11-13 Agents pour le traitement de troubles mettant en jeu la modulation de récepteurs de ryanodine MA37525B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12167732.2A EP2708535A1 (fr) 2012-05-11 2012-05-11 Agents pour le traitement de troubles impliquant la modulation de récepteurs de la ryanodine
PCT/EP2013/057958 WO2013156505A1 (fr) 2012-04-18 2013-04-17 Agents pour le traitement de troubles mettant en jeu la modulation de récepteurs de ryanodine

Publications (2)

Publication Number Publication Date
MA37525A1 MA37525A1 (fr) 2016-05-31
MA37525B1 true MA37525B1 (fr) 2016-12-30

Family

ID=49165460

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37525A MA37525B1 (fr) 2012-05-11 2014-11-13 Agents pour le traitement de troubles mettant en jeu la modulation de récepteurs de ryanodine

Country Status (48)

Country Link
US (3) US20130281512A1 (fr)
EP (2) EP2708535A1 (fr)
JP (1) JP5965542B2 (fr)
KR (1) KR101731459B1 (fr)
CN (1) CN104350045B (fr)
AP (1) AP3591A (fr)
AR (1) AR090712A1 (fr)
AU (1) AU2013248313B2 (fr)
BR (1) BR112014025670B1 (fr)
CA (1) CA2870599C (fr)
CL (1) CL2014002756A1 (fr)
CO (1) CO7091184A2 (fr)
CR (1) CR20140476A (fr)
CU (1) CU24327B1 (fr)
CY (1) CY1115826T1 (fr)
DK (1) DK2653466T3 (fr)
DO (1) DOP2014000230A (fr)
EA (1) EA027922B1 (fr)
EC (1) ECSP14027564A (fr)
ES (1) ES2529890T3 (fr)
GT (1) GT201400222A (fr)
HK (2) HK1192537A1 (fr)
HR (1) HRP20141113T8 (fr)
HU (1) HUE024284T2 (fr)
IL (1) IL235043A (fr)
JO (1) JO3070B1 (fr)
MA (1) MA37525B1 (fr)
MD (1) MD4489C1 (fr)
ME (1) ME01969B (fr)
MX (1) MX350890B (fr)
MY (1) MY167783A (fr)
NI (1) NI201400123A (fr)
NZ (1) NZ701122A (fr)
PE (1) PE20142193A1 (fr)
PH (1) PH12014502256B1 (fr)
PL (1) PL2653466T3 (fr)
PT (1) PT2653466E (fr)
RS (1) RS53711B1 (fr)
RU (1) RU2644350C2 (fr)
SA (1) SA113340479B1 (fr)
SG (1) SG11201406404YA (fr)
SI (1) SI2653466T1 (fr)
TN (1) TN2014000424A1 (fr)
TW (1) TWI507399B (fr)
UA (1) UA113759C2 (fr)
UY (1) UY34742A (fr)
WO (1) WO2013156505A1 (fr)
ZA (1) ZA201407499B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9725429B2 (en) 2013-03-15 2017-08-08 Rosalind Franklin University Of Medicine And Science Furanyl-imine and thiofuranyl-imine compounds for stabilizing ryanodine receptors from aberrant levels of calcium release
CN105209030B (zh) 2013-03-15 2018-06-12 罗莎琳德富兰克林医科大学 用于稳定兰尼碱受体使其免于异常水平的钙释放的化合物
US10676455B2 (en) * 2013-07-18 2020-06-09 Baylor College Of Medicine Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
WO2015197562A1 (fr) * 2014-06-23 2015-12-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement de troubles ou de maladies associées au dysfonctionnement du récepteur de la ryanodine
PL3176164T3 (pl) 2014-07-30 2020-05-18 Aetas Pharma Co. Ltd. Izomer optyczny pochodnej 1-tlenku 1,4-benzotiazepiny oraz farmaceutyczna kompozycja wytworzona z jego użyciem
KR20170102504A (ko) * 2014-12-30 2017-09-11 마이오데릭스, 인코포레이티드 신규한 칼슘 조절제
ES2643856B1 (es) 2016-05-24 2018-08-03 Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea Triazoles para la regulación de la homeostasis de calcio intracelular
WO2018165171A1 (fr) 2017-03-06 2018-09-13 Washington University Traitement du syndrome de wolfram et d'autres troubles de stress du réticulum endoplasmique
JP7282332B2 (ja) * 2017-10-25 2023-05-29 学校法人順天堂 リアノジン受容体阻害薬
US11026905B2 (en) 2018-04-19 2021-06-08 Tvardi Therapeutics, Inc. STAT3 inhibitors
AU2019255755A1 (en) 2018-04-19 2020-12-03 Baylor College Of Medicine STAT3 inhibitors
KR20220131947A (ko) 2020-01-24 2022-09-29 트발디 테라퓨틱스, 인크. 치료 화합물, 제제 및 이의 용도
WO2022099011A1 (fr) 2020-11-06 2022-05-12 Cytokinetics, Inc. 1,4-diazépanones bicycliques et leurs utilisations thérapeutiques
CN116887839A (zh) 2021-01-08 2023-10-13 阿姆果制药有限公司 兰诺定受体调节剂的结晶形式及其用途
WO2022246114A2 (fr) * 2021-05-20 2022-11-24 Armgo Pharma, Inc. Compositions pharmaceutiques comprenant un modulateur du récepteur de la ryanodine et leurs utilisations
WO2023091524A1 (fr) * 2021-11-16 2023-05-25 Armgo Pharma, Inc. Composés thérapeutiques
EP4230196A1 (fr) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Composés à utiliser dans le traitement des dystrophinopathies

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE58901634D1 (de) * 1988-11-05 1992-07-16 Bayer Ag Verfahren zur kernchlorierung von aromatischen kohlenwasserstoffen.
GB9021813D0 (en) * 1990-10-08 1990-11-21 Ici Plc Tricyclic heterocycles
ES2190428T3 (es) 1991-06-28 2003-08-01 Smithkline Beecham Corp Antagonistas biciclicos de fibrinogeno.
ES2113081T3 (es) * 1992-11-09 1998-04-16 Knoll Ag 1,4-benzotiazepinas utiles como agentes neurologicos.
FR2752017B1 (fr) 1996-08-01 1998-10-16 Hispano Suiza Sa Inverseur de poussee de turboreacteur a portes formant ecopes
GB9914745D0 (en) 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
US8022058B2 (en) * 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US20020183307A1 (en) 2000-07-26 2002-12-05 Tremont Samuel J. Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
SK6282003A3 (en) 2000-10-30 2004-02-03 Janssen Pharmaceutica Nv Tripeptidyl peptidase inhibitors
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
JP2007525165A (ja) 2003-03-07 2007-09-06 トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク タイプ１ライアノジン受容体に基づく方法
US20090292119A1 (en) * 2003-10-07 2009-11-26 The Trustees Of Columbia University In The City Of New York Methods for synthesizing benzothiazepine compounds
WO2006101495A1 (fr) 2005-03-23 2006-09-28 Battelle Memorial Institute Systeme d'identification par radio-frequence a fonction avancee
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2007127145A2 (fr) 2006-04-25 2007-11-08 The Trustees Of Columbia University In The City Of New York Procédés et compositions de traitement de l'arythmie cardiaque chez des animaux non humains
WO2008060332A2 (fr) 2006-06-02 2008-05-22 The Trustees Of Columbia University In The City Of New York Méthodes pour traiter ou réduire la fatigue musculaire
WO2008021439A2 (fr) * 2006-08-17 2008-02-21 The Trustees Of Columbia University In The City Of New York Compositions et méthodes de traitement de l'hypertrophie cardiaque
WO2008021432A2 (fr) 2006-08-17 2008-02-21 The Trustees Of Columbia University In The City Of New York Compositions et méthodes de traitement d'états affectant le système nerveux
WO2008064264A2 (fr) 2006-11-20 2008-05-29 Armgo Pharma, Inc. Procédés in vivo d'identification et de criblage de composés qui modulent la liaison de calstabine à un récepteur de ryanodine
JP5458025B2 (ja) * 2008-03-03 2014-04-02 アームゴ・ファーマ・インコーポレーテッド γ−アミノアルキルベンゼンからベンゾチアゼピンを製造する方法
CN101891706B (zh) * 2010-04-09 2013-05-29 复旦大学 3,4-二氢苯并[f][1,4]噻氮杂*类化合物或其盐及其药物用途
WO2012019076A1 (fr) 2010-08-06 2012-02-09 The Trustees Of Columbia University In The City Of New York Compositions et méthodes de traitement prophylactique ou thérapeutique d'une lésion d'ischémie/reperfusion cardiaque
WO2012019071A1 (fr) 2010-08-06 2012-02-09 The Trustees Of Columbia University In The City Of New York Méthodes de traitement prophylactique et thérapeutique de la sarcopénie
WO2012037105A1 (fr) 2010-09-14 2012-03-22 The Trustees Of Columbia University In The City Of New York Procédés de traitement, d'amélioration ou de prévention de troubles et de maladies neuronaux induits par le stress

Also Published As

Publication number Publication date
CL2014002756A1 (es) 2015-06-12
SA113340479B1 (ar) 2015-09-03
MD4489B1 (ro) 2017-06-30
WO2013156505A1 (fr) 2013-10-24
GT201400222A (es) 2018-09-28
MD20140119A2 (ro) 2015-04-30
NI201400123A (es) 2015-03-05
HRP20141113T8 (hr) 2015-11-06
JP5965542B2 (ja) 2016-08-10
NZ701122A (en) 2016-07-29
AU2013248313A1 (en) 2014-10-30
MX350890B (es) 2017-09-25
ZA201407499B (en) 2015-12-23
EA201401141A8 (ru) 2015-08-31
RS53711B1 (en) 2015-04-30
US20140088171A1 (en) 2014-03-27
ES2529890T3 (es) 2015-02-25
ME01969B (me) 2015-05-20
IL235043A (en) 2016-10-31
US20130281512A1 (en) 2013-10-24
CY1115826T1 (el) 2017-01-25
HUE024284T2 (en) 2016-01-28
HRP20141113T1 (hr) 2015-01-02
PE20142193A1 (es) 2014-12-31
PL2653466T3 (pl) 2015-04-30
TW201345900A (zh) 2013-11-16
AP2014008011A0 (en) 2014-10-31
KR101731459B1 (ko) 2017-04-28
MD4489C1 (ro) 2018-01-31
SI2653466T1 (sl) 2015-03-31
DOP2014000230A (es) 2014-12-15
TN2014000424A1 (fr) 2016-03-30
EA201401141A1 (ru) 2015-04-30
CA2870599A1 (fr) 2013-10-24
MX2014012575A (es) 2015-07-06
CN104350045A (zh) 2015-02-11
UY34742A (es) 2013-11-29
BR112014025670B1 (pt) 2020-06-30
TWI507399B (zh) 2015-11-11
SG11201406404YA (en) 2014-11-27
AP3591A (en) 2016-02-15
PH12014502256A1 (en) 2015-02-09
EP2653466A1 (fr) 2013-10-23
US8853198B2 (en) 2014-10-07
CO7091184A2 (es) 2014-10-21
RU2644350C2 (ru) 2018-02-09
UA113759C2 (xx) 2017-03-10
PT2653466E (pt) 2014-12-03
PH12014502256B1 (en) 2015-02-09
MA37525A1 (fr) 2016-05-31
AR090712A1 (es) 2014-12-03
HK1192537A1 (zh) 2014-08-22
EP2653466B1 (fr) 2014-10-29
MY167783A (en) 2018-09-25
CN104350045B (zh) 2016-08-24
KR20150003347A (ko) 2015-01-08
ECSP14027564A (es) 2015-08-31
HK1207073A1 (zh) 2016-01-22
JO3070B1 (ar) 2017-03-15
EP2708535A1 (fr) 2014-03-19
ES2529890T8 (es) 2015-08-24
RU2014145939A (ru) 2016-06-10
CA2870599C (fr) 2016-08-16
CU24327B1 (es) 2018-03-13
EA027922B1 (ru) 2017-09-29
US20140378437A1 (en) 2014-12-25
DK2653466T3 (en) 2015-02-02
CU20140119A7 (es) 2015-03-30
AU2013248313B2 (en) 2016-11-10
JP2015514736A (ja) 2015-05-21
CR20140476A (es) 2014-12-02

Similar Documents

Publication Publication Date Title
MA37525B1 (fr) Agents pour le traitement de troubles mettant en jeu la modulation de récepteurs de ryanodine
MA42397B1 (fr) 4-azaindoles substituées et leur utilisation comme modulatoeurs de la récepteur glun2b
MA54231A (fr) Composés de 2-formyl-3-hydroxyphényloxyméthyle capables de moduler l'hémoglobine
MA38814B2 (fr) Agoniste gitr et antagoniste pd-1 pour leurs utilisations dans le traitement de troubles proliferatifs
MA34474B1 (fr) Agonistes de gpr40
TN2009000324A1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoides
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
MA33334B1 (fr) Derives de l-(piperidine-4-yl)-pyrazole servant de modulateurs de gpr 119
MA37739A1 (fr) Composés et compositions destinés à la modulation de l'activité de l'egfr
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
MA47356A1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA32655B1 (fr) Composés modulant sélectivement le récepteur cb2
EA200900831A1 (ru) Модуляторы никотиновых ацетилхолиновых рецепторов
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex
MA34805B1 (fr) Dérivés de 4-(5-cyano-pyrazole-1-yl)-pipéridine en tant que modulateurs du gpr119
MA38076A1 (fr) Dérivés d'oxazolidin-2-one-pyrimidine
MA34968B1 (fr) Urées asymétriques et utilisations médicales de celles-ci
TN2016000040A1 (fr) Inhibiteurs de porc2 et procedes pour leur utilisation
MA33242B1 (fr) Composes pour le traitement de troubles metaboliques
MX2021015500A (es) Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b.
MA38253A1 (fr) Compositions comprenant de la vortioxétine et du donépézil
MA38867A1 (fr) Antagonistes de v1a pour traiter des troubles du sommeil impliquant un décalage de phase
MA39253A1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA43250B1 (fr) Composés d'oxadiazaspiro pour le traitement de l'abus et la dépendance aux drogues